« Return to News | Drug Sponsors | CROs/Service Providers

Frontage to develop AtheroNova clinical trial supplies

Friday, April 27, 2012 11:59 AM

Frontage, a global CRO based in Ecton, Penn., has signed an agreement to develop clinical trial supplies with AtheroNova, a biotech company focused on R&D of compounds to regress atherosclerotic plaque.

Frontage will commence work on the analysis, formulation, compounding and tabletization of the company's AHRO-001 tablets in advance of the upcoming phase I human clinical studies.

"Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in the coming days," said Thomas W. Gardner, CEO of AtheroNova. "We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months."

Balbir Brar, senior vice president of drug development, AtheroNova, added, "Our utmost confidence stems from previous projects I have worked on with Frontage and have always found their people, facilities and product quality to be some of the best in the industry."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.